Life Science Investing Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
Life Science Investing Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy in Sanfilippo Syndrome Type B
Life Science Investing Spruce Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
Life Science Investing Spruce Biosciences Announces Integrated Long-Term Clinical Data of Tralesinidase Alfa Enzyme Replacement Therapy Demonstrating Profound and Durable Efficacy and Safety in Patients with Sanfilippo Syndrome Type B
